A Phase 3b study of the effects of elexacaftor/tezacaftor/ivacaftor (ELX/TEZ/IVA) on cough and physical activity in people with cystic fibrosis (CF)

Eva Van Braekel; Elke De Wachter; Marcus A Mall; Edward F McKone; Marijke Proesmans; Bonnie W Ramsey; Saioa Vicente; Daniel M. Smith

doi:10.1016/S1569-1993(23)00345-4

A Phase 3b study of the effects of elexacaftor/tezacaftor/ivacaftor (ELX/TEZ/IVA) on cough and physical activity in people with cystic fibrosis (CF)

Eva Van Braekel, Elke De Wachter, Marcus A Mall, Edward F McKone, Marijke Proesmans, Bonnie W Ramsey, Saioa Vicente, Daniel M. Smith

Research output: Contribution to journal › Meeting abstract (Journal)

Abstract

We assessed the impact of ELX/TEZ/IVA treatment on cough
frequency and physical activity using wearable devices in people with CF.

Original language	English
Article number	EPS6.05
Pages (from-to)	S53
Journal	Journal of Cystic Fibrosis
Volume	22
Issue number	suppl 2
DOIs	https://doi.org/10.1016/S1569-1993(23)00345-4
Publication status	Published - Jun 2023
Event	46th European Cystic Fibrosis conference 2023 - vienna, Austria Duration: 7 Jun 2023 → 10 Jun 2023

Keywords

cystic fibrosis
elexacaftor
tezacaftor-ivacaftor

Access to Document

10.1016/S1569-1993(23)00345-4

Handle.net

Persistent link

Cite this

Van Braekel, E., De Wachter, E., Mall, M. A., McKone, E. F., Proesmans, M., Ramsey, B. W., Vicente, S., & Smith, D. M. (2023). A Phase 3b study of the effects of elexacaftor/tezacaftor/ivacaftor (ELX/TEZ/IVA) on cough and physical activity in people with cystic fibrosis (CF). Journal of Cystic Fibrosis, 22(suppl 2), S53. Article EPS6.05. https://doi.org/10.1016/S1569-1993(23)00345-4

@article{d6650a6e54b14a5e86eaa89350df58b0,

title = "A Phase 3b study of the effects of elexacaftor/tezacaftor/ivacaftor (ELX/TEZ/IVA) on cough and physical activity in people with cystic fibrosis (CF)",

abstract = "We assessed the impact of ELX/TEZ/IVA treatment on coughfrequency and physical activity using wearable devices in people with CF.",

keywords = "cystic fibrosis, elexacaftor, tezacaftor-ivacaftor",

author = "{Van Braekel}, Eva and {De Wachter}, Elke and Mall, {Marcus A} and McKone, {Edward F} and Marijke Proesmans and Ramsey, {Bonnie W} and Saioa Vicente and Smith, {Daniel M.}",

year = "2023",

month = jun,

doi = "10.1016/S1569-1993(23)00345-4",

language = "English",

volume = "22",

pages = "S53",

journal = "Journal of Cystic Fibrosis",

issn = "1569-1993",

publisher = "Elsevier",

number = "suppl 2",

note = "46th European Cystic Fibrosis conference 2023 ; Conference date: 07-06-2023 Through 10-06-2023",

}

Van Braekel, E, De Wachter, E, Mall, MA, McKone, EF, Proesmans, M, Ramsey, BW, Vicente, S & Smith, DM 2023, 'A Phase 3b study of the effects of elexacaftor/tezacaftor/ivacaftor (ELX/TEZ/IVA) on cough and physical activity in people with cystic fibrosis (CF)', Journal of Cystic Fibrosis, vol. 22, no. suppl 2, EPS6.05, pp. S53. https://doi.org/10.1016/S1569-1993(23)00345-4

TY - JOUR

T1 - A Phase 3b study of the effects of elexacaftor/tezacaftor/ivacaftor (ELX/TEZ/IVA) on cough and physical activity in people with cystic fibrosis (CF)

AU - Van Braekel, Eva

AU - De Wachter, Elke

AU - Mall, Marcus A

AU - McKone, Edward F

AU - Proesmans, Marijke

AU - Ramsey, Bonnie W

AU - Vicente, Saioa

AU - Smith, Daniel M.

PY - 2023/6

Y1 - 2023/6

N2 - We assessed the impact of ELX/TEZ/IVA treatment on coughfrequency and physical activity using wearable devices in people with CF.

AB - We assessed the impact of ELX/TEZ/IVA treatment on coughfrequency and physical activity using wearable devices in people with CF.

KW - cystic fibrosis

KW - elexacaftor

KW - tezacaftor-ivacaftor

U2 - 10.1016/S1569-1993(23)00345-4

DO - 10.1016/S1569-1993(23)00345-4

M3 - Meeting abstract (Journal)

SN - 1569-1993

VL - 22

SP - S53

JO - Journal of Cystic Fibrosis

JF - Journal of Cystic Fibrosis

IS - suppl 2

M1 - EPS6.05

T2 - 46th European Cystic Fibrosis conference 2023

Y2 - 7 June 2023 through 10 June 2023

ER -

A Phase 3b study of the effects of elexacaftor/tezacaftor/ivacaftor (ELX/TEZ/IVA) on cough and physical activity in people with cystic fibrosis (CF)

Abstract

Keywords

Access to Document

Handle.net

Fingerprint

Cite this